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Background:  Resistance to mammary tumorigenesis in
Copenhagen rats is associated with loss of early preneoplastic
lesions known as intraductal proliferations. The cause of this
disappearance, however, is unknown.
Results: There were no differences in the numbers of lesions
in mammary whole-mounts prepared from Copenhagen or
Wistar–Furth rats at 20 or 30 days after N-methyl-N-nitro-
sourea treatment, but at 37 days there were significantly fewer
lesions in Copenhagen glands. Furthermore, lesions in
Copenhagen glands were exclusively intraductal proliferations,
whereas in Wistar–Furth glands more advanced lesions were
also present. Immunohistochemical staining showed frequent
cyclin D1 overexpression in Wistar–Furth lesions at 37 days,
but not in Copenhagen lesions. There were, however, no
differences in p16INK4a protein expression, bromodeoxyuridine
labeling and apoptotic indices, or mast cell infiltration between
Copenhagen and Wistar–Furth lesions at any time.
Conclusions: Overexpression of cyclin D1 in preneoplastic
lesions may be important in the development of mammary
tumors in susceptible rats, although this overexpression does
not appear to cause significant changes in cell kinetics.
Furthermore, the low levels of cyclin D1 expression in
Copenhagen intraductal proliferations may play a role in the
resistance of these rats to mammary tumorigenesis.
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Introduction
Most strains of rats develop multiple mammary tumors
when initiated with chemicals or radiation. Several strains,
however, are resistant to mammary tumorigenesis induced
by both of these means. The Copenhagen rat is the best
characterized of these strains [1,2], although the mecha-
nism of resistance is still unknown. Recently, linkage
analysis has identified at least four loci that modify
mammary tumorigenesis in the Copenhagen rat, but the
genes have yet to be cloned [3].
In order to characterize the phenotype associated with
resistance, we recently examined mammary whole-mounts
from both Copenhagen and susceptible Wistar–Furth rats
at various times after treatment with the mammary car-
cinogen N-methyl-N-nitrosourea (MNU) [4]. At 15 days
after MNU treatment, we found that both strains had
developed the earliest detectable preneoplastic lesions,
known as intraductal proliferations (IDPs). The majority
of IDPs from both strains contained activating mutations
in the Ha-ras oncogene, a common alteration in MNU-
induced rat mammary adenocarcinomas [5]. By 45 days
after MNU treatment, in addition to IDPs more advanced
lesions such as ductal carcinomas in situ (DCIS) and ade-
nocarcinomas were detectable in the glands from
Wistar–Furth rats. In contrast, the IDPs from Copenhagen
rats failed to progress and instead declined in number,
such that by 60 days after MNU treatment the glands
were essentially free of lesions.
To investigate a potential mechanism that could explain
the failure of the Copenhagen IDPs to progress and their
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subsequent disappearance, we have examined the expres-
sion of cyclin D1 within IDPs and other lesions from
Copenhagen and Wistar–Furth rats. Cyclin D1 has been
shown to be important in the transition from the G1 to the
S phase of the cell cycle, and perturbations in this control
point can lead to neoplastic transformation [6]. Indeed,
cyclin D1 is frequently overexpressed in both human [7]
and rat mammary tumors [8], and is thought to be an
important factor in their development. This notion was
strengthened by studies that showed that mice engineered
to overexpress cyclin D1 in their mammary glands develop
hyperplastic lesions and eventually mammary carcinomas
[9]. Overexpression of cyclin D1 may be an important
event in determining whether preneoplastic lesions go on
to develop into malignant or benign lesions in humans and
is of particular relevance to the present study [10].
In addition to cyclin D1, we also chose to examine expres-
sion of the p16INK4a protein in the lesions, because it is a
specific inhibitor of the cyclin D1–cdk4 complex that drives
the transition from G1 to S in the cell cycle [11]. Expression
of p16INK4a in normal cells is thought to lead to a growth
arrest [11]. In order to relate changes in the expression of
these genes to changes in cell kinetics within the lesions,
we used bromodeoxyuridine to label cells during the S
phase as a measure of the proliferative index and counted
apoptotic cells based on morphology to estimate cell loss.
Finally, we stained lesions for mast cells, because they have
been implicated in promoting the growth of IDPs [12].
Materials and methods
Animals and carcinogen treatment
Copenhagen and Wistar–Furth rats (6–7 weeks old) were
purchased from Harlan Sprague Dawley (Indianapolis,
Indiana, USA), maintained on a 12h light/dark cycle, fed
Harlan Teklad rat chow (6% fat; Harlan Teklad, Madison,
Wisconsin, USA), and were given free access to water.
After 1 week of acclimatization the rats were given an
intraperitoneal injection of 50mg/kg MNU dissolved in
acidified normal saline.
Bromodeoxyuridine treatment and mammary whole-mount
preparation
At 20, 30, and 37 days after MNU treatment, five rats from
each strain selected randomly were given an intraperitoneal
injection of 50mg/kg bromodeoxyuridine (Boehringer,
Laval, Canada) dissolved in phosphate-buffered saline.
Three hours later, they were killed and mammary whole-
mounts prepared, using the technique we described previ-
ously [4].
Paraffin embedding, staining, and immunohistochemistry
Putative lesions in the whole-mounts were microdissected
from the glands, cleared in xylenes, processed through
three changes of paraffin wax, and then embedded in
paraffin wax (Fisher, Whitby, Canada) for sectioning.
Sections (4mm thick) were placed on poly-L-lysine (Sigma,
St Louis, Missouri, USA) coated slides and stained with
hematoxylin and eosin. Positive identification of IDPs,
DCIS, and adenocarcinomas was based on the criteria we
used previously [4]. Serial sections from confirmed lesions
were then used for cyclin D1, p16INK4a, and bromod-
eoxyuridine immunohistochemistry using established
techniques [13–15]. Anti-cycin D1 and anti-p16INK4a anti-
bodies were obtained from Santa Cruz (Santa Cruz, Cali-
fornia, USA) and anti-bromodeoxyuridine antibodies from
Boehringer. Archival rat mammary tumor tissue was used
as a positive control for cyclin D1, because its overexpres-
sion has been reported in these tumors [8]. The levels of
cyclin D1 in the stained samples were scored as negative
(–), low (+), or high (++), based on number of positive cells
in the lesion as well as staining intensity. Because the mea-
surement of staining intensity was somewhat subjective,
the coded samples were also scored independently by a
second individual, with identical results. The percentage
of cyclin D1-positive cells was determined as the number
of positive cells divided by total cell number in a lesion.
The bromodeoxyuridine labeling index was determined
by the number of bromodeoxyuridine-positive cells
divided by total cells in a lesion. Small intestine from bro-
modeoxyuridine-treated rats or livers from partially hepa-
tectomized rats were used as positive controls for staining.
For all immunohistochemistry, the specificity of the stain-
ing was ensured by replacing the primary antibody with 1%
normal sheep serum. In all cases, no staining was observed.
For determination of apoptotic indices, bromodeoxyuri-
dine-stained sections were also scored for apoptotic cells
based on their morphology (pyknotic nuclei, cell shrink-
age) [16]. Because this is a subjective method, samples
were scored independently by two individuals, with
similar results.
For staining of mast cells, samples were deparaffinized in
xylenes, rehydrated through acetone and water, stained in
0.025% toluidine blue (Sigma) for 30s. Slides were washed
in distilled water, dehydrated in acetone, cleared in
xylenes, and mounted using Permount (Fisher). Mast cells
were counted per high power (400×) field of view around
the lesion.
Statistical analyses
For comparison of numbers of lesions, bromodeoxyuridine-
labeling indices, and apoptotic indices at 20, 30, and 37 days
after MNU treatment, t-tests using Bonferroni’s correction
were used. The data were also analyzed by square root
transformation followed by t-tests using Bonferroni’s correc-
tion. For comparison of cyclin D1 staining in Copenhagen
and Wistar–Furth IDPs, a c2 test was used, with the groups
being IDPs that do not overexpress cyclin D1 (– or +) andBreast Cancer Research    Vol 1 No 1 Korkola et al
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IDPs that do overexpress cyclin D1 (++). For comparison of
percentages of cyclin D1-positive cells in Copenhagen and
Wistar–Furth IDPs at day 37, a one-tailed t-test was used.
Results
To examine the expression of cyclin D1 and p16INK4a pro-
teins within lesions from Copenhagen and Wistar–Furth
rats, mammary whole-mounts were prepared at 20, 30, and
37 days after MNU treatment. In order to estimate prolif-
erative indices within the lesions, all rats were adminis-
tered bromodeoxyuridine before killing. As expected, at
20 and 30 days after MNU treatment the number of
lesions in Copenhagen rats was not different from that in
Wistar–Furth rats (Fig. 1). By 37 days after MNU,
however, there were significantly fewer lesions in the
glands of Copenhagen rats (Fig. 1). Furthermore, we
observed only IDPs in the glands of Copenhagen rats,
whereas more advanced lesions such as ductal carcinomas
in situ (DCIS) and small, nonpalpable tumors were also
present in the glands of Wistar–Furth rats at 37 days; this
is consistent with our previous results [4]. Figure 2 shows
the same region of the inguinal mammary gland from
typical whole-mounts from a Wistar–Furth and a Copen-
hagen rat, demonstrating the striking difference in devel-
opment of lesions in the glands at 37 days.
We determined cyclin D1 expression immunohistochemi-
cally in sections from lesions (Fig. 3a–c). The staining
levels were characterized as negative (–), low (+), or high
(++). We observed no staining in either Wistar–Furth or
Copenhagen IDPs at 20 or 30 days after MNU treatment,
or in any normal mammary tissues. At 37 days, however,
there was cyclin D1 staining in 10 out of 17 Wistar–Furth
IDPs, with six of these showing high levels of expression
(overexpression), as shown in Fig. 3b. In contrast, only
three out of nine IDPs from Copenhagen rats showed any
cyclin D1 staining, with all of these being at a low level
(Fig. 3a). A c2 analysis showed that overexpression of
cyclin D1 was significantly higher in Wistar–Furth IDPs
than in Copenhagen IDPs (P<0.05). Furthermore, we
stained the few advanced lesions present in Wistar–Furth
glands at 37 days for cyclin D1, and observed overexpres-
sion in four out of five DCIS and in all of three nonpalpa-
ble adenocarcinomas (Fig. 3c); this is in good agreement
with the published observations that approximately 80%
of rat mammary tumors overexpress cyclin D1 [8,17].
As an additional measure, we determined the mean per-
centage of cells that expressed cyclin D1 within lesions at
37 days. We found that 5.9±3.4% of cells within Copen-
hagen IDPs stained for cyclin D1, compared with
17.5±4.0% for Wistar–Furth IDPs, 22.6±7.5% for
Wistar–Furth DCIS, and 32.1±2.1% for Wistar–Furth ade-
nocarcinomas (all values are means ±standard error of the
mean). Statistical analysis of Copenhagen and Wistar–
Furth IDPs by t-test showed that the percentage of cells
that expressed cyclin D1 was significantly higher in the
Wistar–Furth lesions (P<0.05). It should be noted that it
was not possible to perform Western analysis to confirm
the cyclin D1 expression levels. Suspected lesions must be
microdissected from the whole-mounts, then embedded
and sectioned to confirm their identity, leaving insuffi-
cient tissue for Western analysis.
Next, we determined p16INK4a expression in the sections
by immunohistochemistry (Fig. 3d–f). We observed
similar levels of staining for this protein in all of the
samples from both strains, including normal mammary
tissue, IDPs, DCIS, and tumors.
To measure the proliferative index of IDPs from both
strains we stained samples using an anti-bromodeoxy-
uridine antibody as shown in Fig. 3g–i. The labeling index
was determined as the number of bromodeoxyuridine-
positive cells divided by the total number of cells in the
lesion. The labeling indices in the Copenhagen IDPs
were not different from those in Wistar–Furth rats at
either 20 or 30 days after MNU treatment when there was
no cyclin D1 overexpression in either strain (Fig. 4). At 37
days, when we observed high levels of cyclin D1 staining
in Wistar–Furth lesions but not in Copenhagen lesions,
there were also no differences in the bromodeoxyuridine
labeling indices between the two strains (Fig. 4). Further-
more, there was no significant correlation between label-
ing indices and cyclin D1 expression levels in lesions from
Wistar–Furth rats at this time.
In the same lesions that we determined the bromod-
eoxyuridine labeling indices, we also counted apoptotic
cells based on their morphology. The apoptotic indices are
shown in Fig. 5. There were no significant differences
Figure 1
Number of preneoplastic lesions in the mammary glands of treated
Copenhagen (Cop) and Wistar–Furth (WF) rats at 20, 30, and 37
days after N-methyl-N-nitrosourea treatment. *P < 0.05, versus
Wistar–Furth rats.between the Copenhagen and Wistar–Furth rats at 20, 30,
or 37 days after MNU treatment.
Toluidine blue, which stains mast cells metachromatically,
was used to visualize these cells within sections. Samples
were scored for the number of mast cells per high power
field of view around each lesion. There were 3.6±0.5,
2.8±0.3, and 6.4±0.7 mast cells around Copenhagen IDPs,
and 4.3±0.5, 2.4±0.5, and 6.6±0.8 mast cells around
Wistar–Furth IDPs at 20, 30, and 37 days after MNU,
respectively (all values are means ±standard error of the
mean). There were no significant differences in mast cell
numbers between the two strains at any of the time points.
Discussion
Overexpression of cyclin D1 has been reported in both
human [7] and rat mammary tumors [8]. It has recently
been shown [10] that cyclin D1 overexpression might be a
critical early event in human breast tumor development,
because overexpression of this gene is common in early
lesions that ultimately form malignant breast cancers, but
not in those that form benign tumors. It is thought that rat
mammary tumorigenesis occurs through the progression of
the early IDPs to DCIS and eventually to adenocarcinomas
[18]. Recently, cyclin D1 expression has been investigated
in normal mammary tissue, preneoplastic lesions, and
tumors in a susceptible strain of rat [17]. The percentage of
cyclin D1-positive cells was shown to be very low (approxi-
mately 2.4%) in normal mammary tissue. In IDPs, however,
approximately 13.6% of cells were positive, and this value
increased with each subsequent stage of tumorigenesis such
that approximately 40% of cells within adenocarcinomas
were positive. We reasoned that if cyclin D1 overexpression
is an early event that is necessary for tumorigenesis in the
rat mammary gland, then differences in the expression of
this gene in Wistar–Furth and Copenhagen rats could
account for their different susceptibilities to mammary
tumorigenesis. At 37 days after MNU treatment, when
there were significantly more IDPs in Wistar–Furth than in
Copenhagen glands, we observed cyclin D1 overexpression
only in Wistar–Furth IDPs. This overexpression was mani-
fested as staining that was both more frequent and more
intense than in IDPs from Copenhagen rats. We also found
that the percentage of cyclin D1-positive cells within
Wistar–Furth IDPs was significantly higher than in Copen-
hagen IDPs at day 37. Furthermore, seven out of the eight
DCIS and adenocarcinomas that had developed by this
time in Wistar–Furth rats showed highly overexpressed
cyclin D1 relative to normal tissue. Both the DCIS and ade-
nocarcinomas had higher percentages of cyclin D1-positive
cells than did IDPs, although the number of advanced
lesions present at this time was too few to demonstrate this
difference statistically. It should be noted that our values
for Wistar–Furth lesions are in good agreement with those
reported by Zhu et al [17]. Because cyclin D1 protein levels
are higher in DCIS and adenocarcinomas than in IDPs,
http://breast-cancer-research.com/vol1no1/07oct99/research/3
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Figure 2
Examples of mammary whole-mounts from (a) a Wistar–Furth rat and
(b) a Copenhagen rat, both 37 days after N-methyl-N-nitrosourea
treatment. Note the striking differences between the glands, with
multiple preneoplastic lesions present in the Wistar–Furth gland but
only one putative lesion present in the Copenhagen gland, as indicated
by the arrows. Bar = 1 mm.overexpression of this gene might be important in the tran-
sition from precancerous to cancerous lesions. Furthermore,
the lack of cyclin D1 overexpression in Copenhagen IDPs
may play a role in their inability to progress to DCIS and
Breast Cancer Research    Vol 1 No 1 Korkola et al
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Figure 3
Immunohistochemical staining for (a–c) cyclin D1, (d–f) p16INK4a, and
(g–i) bromodeoxyuridine. Positive staining cells appear brown,
counter-stained negative cells appear purple. (a), (d), and (g) are serial
sections of an intraductal proliferation (IDP) from a Copenhagen rat;
(b), (e), and (h) are serial sections of a large IDP from a Wistar–Furth
rat; and (c), (f), and (i) are serial sections of a tumor from a
Wistar–Furth rat. Note the overexpression of cyclin D1 in Wistar–Furth
lesions (b and c) but not in the Copenhagen IDP (a). All lesions are
from mammary glands of rats 37 days after MNU treatment. (a–f)
1000× magnification and (g–i) 400× magnification.
Figure 4
Bromodeoxyuridine (BrdU) labeling indices in Copenhagen (Cop) and
Wistar–Furth (WF) rats at 20, 30, and 37 days after MNU treatment.
Figure 5
Apoptotic indices in Copenhagen (Cop) and Wistar–Furth (WF)
lesions at 20, 30, and 37 days after MNU treatment.tumors, a notion supported by our observation of only a
single DCIS in a total of 31 MNU-treated Copenhagen rats
from this and our previous study [4].
Transition from the G1 to S phase of the cell cycle is tightly
regulated within cells. Activity of the cyclin D1–cdk4
complex that drives this transition can be blocked by the
p16INK4a protein, leading to growth arrest [11]. In tumors, a
sustained blockage induced by p16INK4a may lead to apopto-
sis [19]. Loss of the G1–S checkpoint control can occur by a
variety of means, including loss of p16INK4a or overexpres-
sion of cyclin D1 [20]. Our staining showed that p16INK4a was
expressed in all samples, but, as described above, cyclin D1
was overexpressed only in Wistar–Furth lesions at day 37.
Therefore, we expected that the Wistar–Furth IDPs would
have a higher labeling index or lower apoptotic index than
those of Copenhagen rats. As expected, at 20 and 30 days
after MNU treatment, when there were no differences in
cyclin D1 expression in IDPs or in number of IDPs between
the two strains, we found no differences in the bromod-
eoxyuridine labeling or apoptotic indices. Surprisingly, at 37
days we found no significant difference in the bromod-
eoxyuridine labeling indices in IDPs from Copenhagen
compared with Wistar–Furth rats, indicating that there was
no correlation between cyclin D1 overexpression and cell
proliferation. Other studies have also found that cyclin D1
overexpression does not correlate with the proliferation rate
in rat mammary tumors [8] or in human tumors [10]. This
indicates that cyclin D1 overexpression may play other roles
in tumorigenesis that are unrelated to the cell cycle. Indeed,
it has been reported that cyclin D1 can transactivate the
estrogen receptor and influence genomic stability [21]. It has
also been found that cyclin D1 overexpression can inhibit
apoptosis [21]. There was no difference, however, in the
apoptotic indices at 37 days between the strains.
Cyclin D1 may provide a promotional stimulus for
Wistar–Furth IDPs, but we were unable to detect an alter-
ation in cell kinetics. It is possible, however, that small per-
turbations in the rates of cell loss and/or cell growth may
occur that would be undetectable in short-term assays. Such
changes could have profound effects over the long period of
tumor development. Indeed, our observation that preneo-
plastic lesions disappear from the glands of Copenhagen rats
indicates that cell loss may be occurring, although rediffer-
entiation of preneoplastic cells to a more normal phenotype
is also plausible, as we have previously hypothesized [4].
It has been postulated by Russo and Russo [12,22] that
there are two populations of IDPs. Initiated plus promoted
IDPs are able to form more advanced lesions such as DCIS
and tumors, whereas the IDPs that are only initiated are
unable to progress [12,22]. Those authors distinguished
initiated plus promoted IDPs from initiated IDPs by the
infiltration of mast cells, which are three times more abun-
dant around the former. They postulated that these mast
cells may be involved in promoting the growth of lesions,
by the secretion of either mitogenic or angiogenic factors.
If mast cells are more abundant surrounding Wistar–Furth
than Copenhagen IDPs, then secretion of mitogenic
factors could lead to overexpression of cyclin D1 in the
former. We found, however, that there were no differences
in the numbers of mast cells surrounding IDPs of the two
strains at any time point. It seems unlikely, therefore, that
mast cell infiltration plays a role in either cyclin D1 overex-
pression or in the resistance of the Copenhagen rat.
It is unclear what mechanism is responsible for the overex-
pression of cyclin D1 we have observed. It has been
reported that the ras oncogene can induce expression of
cyclin D1 [23,24], but it is unlikely that this is involved,
because we have previously shown [4] that similar percent-
ages of Copenhagen and Wistar–Furth IDPs harbor mutant
Ha-ras alleles. Recently, Tetsu and McCormick [25] have
shown that expression of cyclin D1 can also be regulated
through the actions of transcription factors controlled by
the b-catenin and adenomatomous polyposis coli genes in
colon carcinoma cells [25]. Those authors speculated that
abnormal levels of b-catenin can contribute to the accumu-
lation and overexpression of the cyclin D1 protein and
hence transformation. The b-catenin pathway, therefore,
merits investigation in rat mammary tumorigenesis.
In conclusion, we measured several parameters that could
potentially be involved in the resistance of the Copenhagen
rat to mammary tumorigenesis. We found no differences in
the number of lesions in Copenhagen compared with
Wistar–Furth mammary glands at 20 or 30 days after MNU
treatment, but at 37 days there were significantly fewer
lesions in the Copenhagen glands. Furthermore, by this
time advanced lesions such as DCIS and adenocarcinomas
were present in Wistar–Furth glands, whereas no such
lesions were observed in Copenhagen rats. Immunohisto-
chemical staining of lesions from both strains indicated that
cyclin D1 was frequently overexpressed in Wistar–Furth
lesions at 37 days, but not in Copenhagen lesions from the
same time. Expression of p16INK4a protein, bromodeoxyuri-
dine labeling and apoptotic indices, and mast cell infiltra-
tion around lesions were not significantly different between
the two strains at any time. These findings indicate that
overexpression of cyclin D1 might play a fundamental role
in the progression of IDPs to DCIS and adenocarcinomas
during rat mammary tumorigenesis. Furthermore, this gene
might also play a role in the resistance of Copenhagen rats
to MNU-induced mammary tumorigenesis.
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